PhRMA Takes Aim at Medicare Price Negotiation as HHS Digs In

Policies aimed at slowing price growth in the most expensive drug categories could result in slightly fewer drugs coming to market, according to an analysis of the issue prepared by the Congressional Budget Office (CBO). While the pharmaceutical industry has used the report to back up its longstanding claims that drug development would be irreparably harmed by federal intervention on prices, employer plan sponsors and other payer groups insist that the impact of drug pricing policies on drug development would be marginal at most. “The model uses estimates of changes in expected future profits or development costs to estimate the …

Read the source article at AIS Health
2021-09-09 18:57:49